Scholar Rock (SRRK) Projected to Post Quarterly Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $37.16 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The stock’s 50-day moving average is $41.69 and its two-hundred day moving average is $28.86. The firm has a market cap of $3.48 billion, a P/E ratio of -15.81 and a beta of 0.50.

Insider Transactions at Scholar Rock

In related news, CFO Edward H. Myles sold 12,539 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $554,223.80. Following the completion of the sale, the chief financial officer now owns 148,549 shares in the company, valued at $6,565,865.80. This represents a 7.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now owns 111,084 shares of the company’s stock, valued at approximately $4,154,541.60. The trade was a 38.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,974 shares of company stock worth $5,927,710. 19.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SRRK. HC Wainwright upped their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a research report on Wednesday, January 29th. Finally, Truist Financial upped their target price on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.